Pathstone Family Office, LLC Neurocrine Biosciences Inc Transaction History
Pathstone Family Office, LLC
- $15.6 Billion
- Q3 2023
A detailed history of Pathstone Family Office, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pathstone Family Office, LLC holds 2,870 shares of NBIX stock, worth $327,180. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,870Holding current value
$327,180% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding NBIX
# of Institutions
640Shares Held
95.2MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$525 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$281 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$269 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...